On 4/19/2017, Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) closed at $157.08 in last trading day. After noting the initial trading entry at $156.55, it reached to a day’s high of $157.65 and moved to a day’s low of $155.86. The recent daily volume was 477.34 thousand as contrast to it’s an average volume of 706.03 thousand.
The last close of the IDEXX Laboratories, Inc. stock reflects that it traded up +3.07% from its 50-day moving average of $152.40. The stock traded above +22.30% to its 200-day MA of $128.44. Furthermore, it moved lower -0.36% from its 52-week high of $157.65 and +95.93% up from $80.17, which is 52-week low of the stock.
During the last month, IDEXX Laboratories, Inc.’s (IDXX) has changed 3.66% and performed 41.17% over the last 6 months. The mean rating score for this stock is at 2.50. This rating scale contains from 1 to 5 with 5 representing a Strong Sell, 1 signifying a Strong Buy and 3 demonstrating a Hold. The Volatility was noted at 1.37% in recent month and observed Weekly Volatility of 1.23%.
IDEXX Laboratories, Inc., together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. It operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments. The company provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assays; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community. It also offers diagnostic and health-monitoring products for livestock, poultry, and dairy markets; products that test water for various microbiological contaminants; and point-of-care electrolytes and blood gas analyzers that are used in the human point-of-care medical diagnostics market. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was founded in 1983 and is headquartered in Westbrook, Maine.
Intra-Cellular Therapies Inc. (NASDAQ:ITCI) finalized the last transaction at value of $13.65, with a daily change of +1.94% or +0.26 points. The company maintained volume of 449.85 thousand shares. In past trading day, the stock hit the maximum price of $13.73 and touched to minimum value of $13.27. It has a market cap of $ 592.55M.
As of last trade close, the stock is trading downside -69.80% from its one year high of $45.20 and moved +30.94% upward from $10.43, which is one year low of the stock.
The stock traded below -7.46% from its 50-day moving average of $14.75. Furthermore, the stock moved -4.51% to its 200-day MA of $ 14.30.
Intra-Cellular Therapies, Inc.’s (ITCI) moved with shift of -2.29% in the past week. Over the last three months, the shares of the company have changed -3.60% and performed 3.02% over the last six months. The stock currently has Monthly Volatility of 5.93% and Weekly Volatility of 3.54%.
Intra-Cellular Therapies, Inc., a biopharmaceutical company, engages in developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases and diseases of the elderly, including Parkinson’s and Alzheimer’s disease. The company is developing its lead drug candidate, lumateperone, known as ITI-007, for the treatment of schizophrenia, bipolar disorder, behavioral disturbances in patients with dementia, depression, and other neuropsychiatric and neurological disorders. Lumateperone, a molecule, is in Phase III clinical development for the treatment of schizophrenia, bipolar depression, and agitation associated with dementia, including Alzheimer’s disease. The company is also utilizing its phosphodiesterase platform and other proprietary chemistry platforms to develop drugs for the treatment of central nervous system and other disorders. Intra-Cellular Therapies, Inc. is headquartered in New York, New York.